C2 PHARMA Expands API Portfolio with Global Regulatory Access Ahead of CPHI Barcelona

C2 PHARMA has expanded their API portfolio global access with new regulatory submissions and approvals, a pending new product launch and have signed on a new CMO, SMS Lifesciences. 

Along with the C-DMF and CEP approvals, the filings continue to grow across C2 PHARMA’s API portfolio. The most recent submissions include: 

o   Brimonidine Tartrate

          o  CADIFA under submission

o   Bitmatoprost

         o Canadian-DMF under submission

o   Pilocarpine Hydrochloride Micronized

          o  Korean K-DMF under submission

o   Tropicamide

         o China C-DMF under submission

 
The company will be exhibiting at CPHI Worldwide 2023 in Barcelona from the 24th to the 26th of October 2023 in Hall 4, Booth D49 with its affiliates, Logisitics4Pharma and ASM Research Chemicals. To schedule a meeting please reach out to [email protected].